Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Central obesity in children represents a significant public health concern due to its strong association with an elevated risk of metabolic and cardiovascular disorders. The systemic immune inflammation index (SII) has been implicated in the pathophysiology of obesity-related chronic inflammation. Despite its potential relevance, the specific relationship between central obesity and SII in the pediatric population remains insufficiently explored. The objective of this study was to examine the relationship between SII and central obesity, with a particular focus on the potential of SII as a predictor of central obesity and a means of preventing obesity at an early stage of life.
Methods: Waist-to-height ratio (WHtR), subcutaneous fat, and visceral fat were employed as obesity proxies. Central obesity was defined according to WHtR with a cutoff value of 0.46. The implications of SII on central obesity were examined in a sample of 4,730 individuals in 2021 and validated through a prospective study involving 1,425 subjects in 2023. Cross-sectional associations between SII and central obesity were examined using binomial logistic regression models and generalized linear models. The restricted cubic spline regression was used to explore the non-linear relationship between SII and obesity indicators. In a prospective study, we employed a modified Poisson regression model to investigate the potential causal relationship between SII and central obesity.
Results: Cross-sectionally, adolescents in the highest quartile of SII levels exhibited the greatest risk for central obesity(OR=3.07, 95% CI:2.45~3.87) when compared to those in the lowest quartile. Subgroup analyses showed that higher SII was associated with central obesity. Longitudinally, individuals in the highest SII quartile were found to have the highest risk of developing central obesity (RR=1.83, 95% CI:1.18~2.83) over time.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880016 | PMC |
| http://dx.doi.org/10.3389/fimmu.2025.1546612 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Contribution of metabolism-independent glucose sensing to metabolic homeostasis.
Trends Endocrinol Metab
September 2025
Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40506, USA; Barnstable Brown Diabetes and Obesity Research Center, University of Kentucky, Lexington, KY 40506, USA. Electronic address:
Glucose sensing and signaling are central to cellular metabolic machinery for the regulation of metabolic homeostasis. Glucose sensing has been almost always assumed to be coupled with glucose metabolism; however, recent findings have unraveled metabolism-independent sensing mechanisms. Here, we discuss whether glucose transporters (GLUTs) and sodium-glucose co-transporters (SGLTs) may also function as glucose sensors independent of their roles in transporting glucose.
View Article and Find Full Text PDFEstablished and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond.
Heart Lung Circ
September 2025
Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia; Department of Cardiology, Central Adelaide Local Health Network, Adelaide, SA,
Cardiovascular-kidney-metabolic (CKM) syndrome is a term that is increasingly used to describe interconnected conditions that lead to poor health outcomes, including cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. Historically, there have been very few targeted pharmacotherapies available that have changed cardiovascular outcomes for people with CKM syndromes; however, over the past decade, new pharmacologic options have rapidly expanded, with strong evidence for cardiovascular and kidney protective benefits in CKM conditions. Of note, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have emerged as key therapeutic options and are now widely guideline-endorsed.
View Article and Find Full Text PDFIs active commuting associated with metabolic syndrome in adults, adolescents, and children? a systematic review and meta-analysis.
Nutr Metab Cardiovasc Dis
July 2025
Instituto de Investigación e Innovación Biomédica de Cádiz, (INiBICA), Cádiz, Spain; GALENO Research Group, Department of Physical Education, Faculty of Education Sciences, University of Cádiz, Puerto Real, Cadiz, Spain; Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain; UGC
Aims: The prevalence of metabolic syndrome (MetS) is increasing annually across all age groups, raising the risk of morbidity, mortality, diabetes and cardiovascular disease in adults, adolescents, and children. Active commuting (AC) provides an opportunity to increase physical activity and reduce the MetS risk. The purpose of this study was to synthesize the available evidence on the prevalence of MetS and MetS risk factors in relation to AC vs non-active commuting among adults, adolescents, and children.
View Article and Find Full Text PDFProspective associations of dynapenic abdominal obesity status with distinct trajectories of depressive symptoms: A national cohort study.
Clin Nutr
May 2025
Department of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Department of Clinical Epidemiol
Background And Aims: Dynapenic abdominal obesity has been shown as a risk factor for adverse outcomes. There is no evidence on the longitudinal association of this condition with different courses of depressive symptoms. This study aimed to investigate the association of dynapenic abdominal obesity status with the risk of distinct trajectories of depressive symptoms.
View Article and Find Full Text PDFEuropean survey on metabolic and cardiovascular risk in Cushing syndrome.
J Endocrinol Invest
September 2025
Department of Medicine-DIMED, University of Padova, Padova, Italy.
Background: Cushing's syndrome (CS) is associated with increased metabolic and cardiovascular (CV) risk factors and morbidities. Evidence-based guidelines for the management of these issues in active or remitted CS are not available, so best practice is derived from guidelines developed for the general population. We aimed to evaluate the awareness and practice variation for CV comorbidities of CS across Reference Centres (RCs) of the European Reference Network on Rare Endocrine Conditions (Endo-ERN).
View Article and Find Full Text PDF